Compare Novartis AG (NVS) vs Zillow Group Inc Class A (ZG) Price & Performance

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Zillow Group (ZG) trades at $32.97, down 3.23% today, reflecting near-term pressure amid a securities class action deadline. The stock shows a bearish technical signal with support at $32 and resistance at $35. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 149 indicate high expectations. Recent Q2 2026 earnings beat expectations with 18% revenue growth, driven by the Preferred Agent model.

The outlook is mixed: analyst consensus is a Buy with a $47.56 price target, suggesting 44% upside, but risks include legal overhangs from the class action and a high P/E requiring sustained growth. Investors should weigh the bullish monetization shift against near-term volatility and profitability challenges.